CLX vs PG vs TEVA Stock Comparison

Clorox, Procter & Gamble and Teva Pharmaceutical Industries Prices as of Nov 13, 2026 Peers: Industry group
CLX Clorox Co /De/
$109.46 +28.8% 1M +5.0% 1Y
Market cap
$13.39B
P/E
19.8x
Revenue (TTM)
$7.20B
Div. yield
0.04%
Household Products Consumer Staples
4 wins
PG PROCTER & GAMBLE Co
$169.81 +8.5% 1M +14.8% 1Y
Market cap
$401.30B
P/E
25.0x
Revenue (TTM)
$87.92B
Div. yield
–
Household Products Consumer Staples
4 wins

Head to Head

11 decided of 12

Procter & Gamble leads on 4 of the 12 questions below (Procter & Gamble 4, Clorox 4, Teva Pharmaceutical Industries 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCLXPGTEVALeader
Larger companyMarket capitalisation $13.39B $401.30B $50.31B PG
Cheaper on earningsLower P/E, profitable companies only 19.8x 25.0x 99.4x CLX
Cheaper on forward earningsLower price / next fiscal year consensus EPS 18.3x 25.1x 22.7x CLX
Faster revenue growthRevenue growth, trailing twelve months +6.3% +3.5% +2.7% CLX
More profitableNet margin, trailing twelve months 9.4% 18.2% 2.9% PG
Better return on capitalReturn on invested capital 26.7% 17.2% 5.9% CLX
Less leveragedLower net debt / EBITDA 2.4x 1.0x 5.2x PG
Higher dividend yieldTrailing dividend yield 0.04% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +5.0% +14.8% +74.4% TEVA
Better 5-year returnAnnualised price return, 5 years -8.0%/yr +3.0%/yr +36.2%/yr TEVA
Less volatileAnnualised volatility, 1 year 33.4% 21.1% 33.4% PG
Higher overall scoreMean of the five percentile scores vs peers 59/100 58/100 62/100 TEVA

Percentile Scorecard

CLXPGTEVA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCLXPGTEVA
Valuation 76 #14 of 55 41 #33 of 55 82 #120 of 660
Growth 59 #22 of 52 51 #26 of 52 68 #201 of 619
Profitability 86 #8 of 50 92 #5 of 50 86 #87 of 595
Financial Health 16 #50 of 59 62 #23 of 59 11 #608 of 683
Shareholder Returns 58 #14 of 32 45 #18 of 32 –
Overall 59 58 62
  • CLX ranked among 60 companies in Household and Personal Products
  • PG ranked among 60 companies in Household and Personal Products
  • TEVA ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCLXPGTEVASPY
1 month +28.8%+8.5%+9.3% -2.0%
3 months +3.5%+17.5%+21.1% -2.8%
6 months +21.0%+19.9%+29.9% +2.0%
Year to date +8.6%+18.5%+42.7% +10.6%
1 year +5.0%+14.8%+74.4% +12.2%
3 years -19.8%+11.6%+399.9% +68.1%
3 years, per year -7.1%+3.7%+71.0% +18.9%
5 years -34.1%+15.9%+368.3% +61.4%
5 years, per year -8.0%+3.0%+36.2% +10.1%
10 years -3.2%+103.2%+9.6% +248.5%
10 years, per year -0.3%+7.3%+0.9% +13.3%

Risk

MeasureCLXPGTEVASPY
Volatility, 1Y 33.4%21.1%33.4% 13.6%
Downside volatility, 1Y 35.7%20.3%27.5% 13.9%
Beta vs S&P 500, 1Y 0.37-0.030.59 1.00
Return / volatility, 1Y 0.150.702.23 0.90
Max drawdown, 5Y -56.9%-24.6%-43.7% -25.4%
From 52-week high -13.9%0.0%0.0% -3.2%
52-week high $127.16$169.81$44.54 $779.14
52-week low $80.38$138.04$24.21 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCLXPGTEVA
P/E now vs peer median 19.7xmedian 21.1x 24.6xmedian 21.1x 102.6xmedian 17.0x
P/S now vs peer median 1.8xmedian 2.2x 4.5xmedian 2.2x 3.0xmedian 8.4x
EV/EBITDA now vs peer median 8.7xmedian 14.0x 18.1xmedian 14.0x 26.7xmedian 14.6x
P/FCF now vs peer median 29.2xmedian 17.3x 25.7xmedian 17.3x 42.0xmedian 19.0x
P/B now vs peer median 109.4xmedian 1.9x 7.1xmedian 1.9x 6.5xmedian 2.0x
PEG now vs peer median 0.20median 0.87 9.29median 0.87 3.39median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCLXPGTEVA
Revenue $7.20B $87.92B $17.23B
Gross profit $3.02B $43.77B $9.22B
Operating income $1.82B $19.83B $1.44B
Net income $692.00M $16.12B $508.00M
Free cash flow $453.00M $15.34B $1.24B
R&D $117.00M – $1.76B
EPS (diluted) $5.55 $6.66 $0.43
Cash & equivalents $184.00M $15.37B $4.09B
Total debt $5.16B $38.93B $16.72B
Shares (diluted) 122.03M 2.41B 1.18B
Enterprise value $11.65B $352.86B $35.28B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCLXPGTEVA
P/E 19.7x 24.6x 102.6x
P/FCF 29.2x 25.7x 42.0x
P/Operating cash flow 20.0x 19.8x 29.4x
P/S 1.8x 4.5x 3.0x
P/B 109.4x 7.1x 6.5x
P/Tangible book -28.0x 11.6x 11.1x
EV/EBITDA 8.7x 18.1x 26.7x
EV/EBIT 10.0x 21.0x 45.0x
EV/Revenue 2.5x 4.7x 3.7x
EV/FCF 40.2x 27.2x 52.3x
EV/Operating cash flow 27.5x 20.9x 36.5x
PEG (3Y EPS CAGR) 0.20 9.29 3.39

Growth

14 metrics
MetricCLXPGTEVA
Revenue growth (1Y) 6.3% 3.5% 2.7%
Revenue CAGR (3Y) 0.8% 1.8% 4.1%
Gross profit growth (1Y) 0.5% 1.1% 9.7%
Gross profit CAGR (3Y) 2.4% 2.3% 9.6%
Operating income growth (1Y) 3.3% -3.3% -21.5%
Operating income CAGR (3Y) 7.2% 1.5% 46.4%
Net income growth (1Y) -13.8% -4.4% -23.3%
Net income CAGR (3Y) 88.1% 1.7% 30.3%
EPS growth (1Y) -13.7% -3.2% -30.1%
EPS CAGR (3Y) 100.3% 2.7% 30.2%
Operating cash flow growth (1Y) -22.4% 5.2% 66.0%
Operating cash flow CAGR (3Y) -12.8% 4.0% 15.2%
Free cash flow growth (1Y) -28.8% 2.7% 113.8%
Free cash flow CAGR (3Y) -17.1% 1.7% 26.7%

Profitability

14 metrics
MetricCLXPGTEVA
Gross margin 41.9% 49.8% 53.5%
EBITDA margin 29.0% 26.2% 14.0%
Operating margin 25.3% 22.6% 8.3%
Pretax margin 12.4% 23.2% 2.1%
Net margin 9.4% 18.2% 2.9%
FCF margin 6.3% 17.4% 7.2%
Operating cash flow margin 9.2% 22.7% 10.3%
Return on equity 371.0% 29.4% 6.5%
Return on assets 8.9% 12.4% 1.3%
Return on invested capital 26.7% 17.2% 5.9%
Return on capital employed 37.5% 23.4% 5.9%
Asset turnover 0.9x 0.7x 0.4x
Cash conversion (OCF / net income) 1.0x 1.2x 3.5x
Stock comp / revenue 0.7% 0.6% 1.0%

Financial Health

11 metrics
MetricCLXPGTEVA
Debt / assets 65.9% 29.2% 41.8%
Debt / equity 42.6x 0.7x 2.1x
Net debt / EBITDA 2.4x 1.0x 5.2x
Debt / FCF 11.4x 2.5x 13.5x
Liabilities / assets 98.5% 58.4% 80.1%
Equity / assets 1.5% 41.6% 19.9%
Interest coverage 11.5x 22.0x –
Current ratio 0.7x 0.7x 0.9x
Quick ratio 0.3x 0.5x 0.5x
Cash ratio 0.1x 0.3x 0.3x
Altman Z-score 2.60 5.53 1.02

Shareholder Returns

7 metrics
MetricCLXPGTEVA
Dividend yield 4.5% 2.5% –
Net buyback yield 1.2% 0.8% –
Shareholder yield 5.8% 3.4% 0.0%
Payout ratio (earnings) 87.0% – –
Payout ratio (FCF) 132.9% – –
Dividend growth (1Y) 0.0% – –
Dividend CAGR (3Y) 0.8% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCLXPGTEVA
Forward P/E 18.3xFY2027 25.1xFY2027 22.7xFY2026
EPS, next fiscal year $5.97FY2027 $6.76FY2027 $1.96FY2026
EPS growth, next FY +8.0%FY2027 -1.9%FY2027 -33.1%FY2026
EPS growth, the year after -1.3% +16.6% +65.3%
Revenue, next fiscal year $8.10BFY2027 $86.29BFY2027 $15.89BFY2026
Revenue growth, next FY +20.6%FY2027 -0.9%FY2027 -8.0%FY2026
Revenue growth, the year after -8.7% +0.2% +16.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCLXPGTEVA
Held by institutions 85.6% 69.8% 62.7%
Institutions holding 1,056 4,036 672
Change in shares held, QoQ +4.2% +2.0% +8.6%
Institutions buying 542 1,878 359
Institutions selling 356 1,701 192
Buyers to sellers 1.52 1.10 1.87

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CLXPGTEVA
CLX 1.00 0.54 0.08
PG 0.54 1.00 0.06
TEVA 0.08 0.06 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CLX, PG and TEVA?

Procter & Gamble (PG) is the largest by market capitalisation: Clorox (CLX) $13.39B, Procter & Gamble (PG) $401.30B, Teva Pharmaceutical Industries (TEVA) $50.31B.

Which stock is cheaper, CLX, PG and TEVA?

Clorox (CLX) trades on the lowest price-to-earnings ratio (Clorox (CLX) 19.8x, Procter & Gamble (PG) 25.0x, Teva Pharmaceutical Industries (TEVA) 99.4x). On next year's consensus earnings, Clorox (CLX) is cheapest (Clorox (CLX) 18.3x, Procter & Gamble (PG) 25.1x, Teva Pharmaceutical Industries (TEVA) 22.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Clorox (CLX) grew revenue fastest over the trailing twelve months: Clorox (CLX) +6.3%, Procter & Gamble (PG) +3.5%, Teva Pharmaceutical Industries (TEVA) +2.7%.

Which company is more profitable?

Procter & Gamble (PG) has the highest net margin (Clorox (CLX) 9.4%, Procter & Gamble (PG) 18.2%, Teva Pharmaceutical Industries (TEVA) 2.9%). On return on invested capital, Clorox (CLX) leads (Clorox (CLX) 26.7%, Procter & Gamble (PG) 17.2%, Teva Pharmaceutical Industries (TEVA) 5.9%).

Which stock has performed better?

Over the past year Teva Pharmaceutical Industries (TEVA) returned the most: Clorox (CLX) +5.0%, Procter & Gamble (PG) +14.8%, Teva Pharmaceutical Industries (TEVA) +74.4%. Over five years, Teva Pharmaceutical Industries (TEVA) compounded fastest (Clorox (CLX) -8.0%/yr, Procter & Gamble (PG) +3.0%/yr, Teva Pharmaceutical Industries (TEVA) +36.2%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Clorox (CLX) 0.04%, Procter & Gamble (PG) 0.00%, Teva Pharmaceutical Industries (TEVA) 0.00%. Procter & Gamble (PG) and Teva Pharmaceutical Industries (TEVA) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Procter & Gamble (PG) has been the steadiest (Clorox (CLX) 33.4%, Procter & Gamble (PG) 21.1%, Teva Pharmaceutical Industries (TEVA) 33.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CLX, PG and TEVA?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Procter & Gamble (PG) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.